2.43 USD
+0.21 (+9.46%)
Overall PACB gets a fundamental rating of 2 out of 10. We evaluated PACB against 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of PACB have multiple concerns. PACB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PACB has reported negative net income.
PACB had a negative operating cash flow in the past year.
In the past 5 years PACB reported 4 times negative net income.
PACB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -62.71%, PACB is not doing good in the industry: 86.21% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -1395.49%, PACB is doing worse than 93.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.71% | ||
| ROE | -1395.49% | ||
| ROIC | N/A |
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 28.10%, PACB is not doing good in the industry: 75.86% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of PACB has declined.
PACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
2. Health
2.1 Basic Checks
PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PACB has more shares outstanding
The number of shares outstanding for PACB has been increased compared to 5 years ago.
Compared to 1 year ago, PACB has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -5.70, we must say that PACB is in the distress zone and has some risk of bankruptcy.
PACB has a Altman-Z score of -5.70. This is amonst the worse of the industry: PACB underperforms 86.21% of its industry peers.
PACB has a Debt/Equity ratio of 17.88. This is a high value indicating a heavy dependency on external financing.
PACB's Debt to Equity ratio of 17.88 is on the low side compared to the rest of the industry. PACB is outperformed by 93.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 17.88 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.7 |
ROIC/WACCN/A
WACC8.02%
2.3 Liquidity
A Current Ratio of 6.24 indicates that PACB has no problem at all paying its short term obligations.
The Current ratio of PACB (6.24) is better than 86.21% of its industry peers.
A Quick Ratio of 5.40 indicates that PACB has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.40, PACB belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.24 | ||
| Quick Ratio | 5.4 |
3. Growth
3.1 Past
PACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.68%.
The Revenue for PACB has decreased by -10.72% in the past year. This is quite bad
The Revenue has been growing by 11.12% on average over the past years. This is quite good.
EPS 1Y (TTM)-50.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
Revenue 1Y (TTM)-10.72%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-3.82%
3.2 Future
Based on estimates for the next years, PACB will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.41% on average per year.
PACB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.38% yearly.
EPS Next Y-0.38%
EPS Next 2Y29.05%
EPS Next 3Y19.56%
EPS Next 5Y12.41%
Revenue Next Year3.4%
Revenue Next 2Y9.12%
Revenue Next 3Y12.77%
Revenue Next 5Y14.38%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
Also next year PACB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PACB's earnings are expected to grow with 19.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.05%
EPS Next 3Y19.56%
5. Dividend
5.1 Amount
No dividends for PACB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PACB (11/24/2025, 3:02:57 PM)
2.43
+0.21 (+9.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners57.25%
Inst Owner Change-6.29%
Ins Owners0.98%
Ins Owner Change-0.23%
Market Cap729.90M
Revenue(TTM)154.58M
Net Income(TTM)-503.63M
Analysts75.29
Price Target2.15 (-11.52%)
Short Float %11.76%
Short Ratio3.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.71%
Min EPS beat(2)16.15%
Max EPS beat(2)19.26%
EPS beat(4)2
Avg EPS beat(4)-186.36%
Min EPS beat(4)-646.96%
Max EPS beat(4)19.26%
EPS beat(8)3
Avg EPS beat(8)-115.13%
EPS beat(12)5
Avg EPS beat(12)-74.24%
EPS beat(16)6
Avg EPS beat(16)-57.09%
Revenue beat(2)1
Avg Revenue beat(2)-0.34%
Min Revenue beat(2)-6.27%
Max Revenue beat(2)5.6%
Revenue beat(4)2
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-6.27%
Max Revenue beat(4)5.6%
Revenue beat(8)2
Avg Revenue beat(8)-4.21%
Revenue beat(12)6
Avg Revenue beat(12)0.59%
Revenue beat(16)6
Avg Revenue beat(16)-0.48%
PT rev (1m)5.56%
PT rev (3m)6.74%
EPS NQ rev (1m)0.33%
EPS NQ rev (3m)-0.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.38%
Revenue NQ rev (1m)-2.83%
Revenue NQ rev (3m)-2.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 20.22 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.2
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.51
BVpS0.12
TBVpS-0.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.71% | ||
| ROE | -1395.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.1% | ||
| FCFM | N/A |
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
F-Score3
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 17.88 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.17% | ||
| Cap/Sales | 5.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.24 | ||
| Quick Ratio | 5.4 | ||
| Altman-Z | -5.7 |
F-Score3
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)74.27%
Cap/Depr(5y)63.44%
Cap/Sales(3y)7.21%
Cap/Sales(5y)5.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
EPS Next Y-0.38%
EPS Next 2Y29.05%
EPS Next 3Y19.56%
EPS Next 5Y12.41%
Revenue 1Y (TTM)-10.72%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-3.82%
Revenue Next Year3.4%
Revenue Next 2Y9.12%
Revenue Next 3Y12.77%
Revenue Next 5Y14.38%
EBIT growth 1Y-90.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.57%
EBIT Next 3Y20.23%
EBIT Next 5Y15.78%
FCF growth 1Y52.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.16%
OCF growth 3YN/A
OCF growth 5YN/A
PACIFIC BIOSCIENCES OF CALIF / PACB FAQ
What is the ChartMill fundamental rating of PACIFIC BIOSCIENCES OF CALIF (PACB) stock?
ChartMill assigns a fundamental rating of 2 / 10 to PACB.
What is the valuation status for PACB stock?
ChartMill assigns a valuation rating of 0 / 10 to PACIFIC BIOSCIENCES OF CALIF (PACB). This can be considered as Overvalued.
Can you provide the profitability details for PACIFIC BIOSCIENCES OF CALIF?
PACIFIC BIOSCIENCES OF CALIF (PACB) has a profitability rating of 0 / 10.
What is the expected EPS growth for PACIFIC BIOSCIENCES OF CALIF (PACB) stock?
The Earnings per Share (EPS) of PACIFIC BIOSCIENCES OF CALIF (PACB) is expected to decline by -0.38% in the next year.